SeekingAlpha · Aug 1, 2026
Phathom Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-01. The following slide deck was published by Phathom Pharmaceuticals, Inc.
PH
NASDAQ · PHAT
Phathom Pharmaceuticals, Inc.
Healthcare · Biotechnology
$9.58
Up+$0.40 (+4.36%)
Updated Aug 16, 2026, 7:59 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.04B
- P/E ratio
- -3.89
- Dividend yield
- 0.00%
- 52-week range
- $8.21 – $18.31
- Volume
- 969.08K
- Avg. volume
- 1.06M
Price performance
PHAT price history
1M range · 20 trading sessions · Daily adjusted prices
PHAT closed at $9.58 after 20 trading sessions, down 10.05% for the selected period.
- Last close
- $9.58
- Period change
- -10.05%
- Period low
- $8.23
- Period high
- $11.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $9.13 | $9.59 | $9.075 | $9.58 | 969.08K |
| Aug 13, 2026 | $9.25 | $9.3861 | $8.97 | $9.18 | 1.21M |
| Aug 12, 2026 | $8.51 | $9.185 | $8.47 | $9.17 | 2.08M |
| Aug 11, 2026 | $8.61 | $8.82 | $8.465 | $8.51 | 1.79M |
| Aug 10, 2026 | $8.44 | $8.89 | $8.405 | $8.57 | 2.15M |
| Aug 7, 2026 | $8.48 | $8.61 | $8.30 | $8.55 | 2.31M |
| Aug 6, 2026 | $8.38 | $8.62 | $8.29 | $8.39 | 1.47M |
| Aug 5, 2026 | $8.49 | $8.7599 | $8.21 | $8.23 | 1.65M |
| Aug 4, 2026 | $9.00 | $9.03 | $8.32 | $8.45 | 2.19M |
| Aug 3, 2026 | $8.75 | $9.23 | $8.45 | $8.98 | 1.53M |
| Jul 31, 2026 | $9.10 | $9.49 | $8.665 | $8.75 | 3.31M |
| Jul 30, 2026 | $8.90 | $10.21 | $8.80 | $9.03 | 7.62M |
| Jul 29, 2026 | $11.92 | $12.00 | $11.60 | $11.64 | 729.49K |
| Jul 28, 2026 | $11.41 | $12.24 | $11.272 | $11.66 | 689.28K |
| Jul 27, 2026 | $11.60 | $12.12 | $11.49 | $11.95 | 664.73K |
| Jul 24, 2026 | $11.66 | $11.70 | $11.34 | $11.44 | 936.45K |
| Jul 23, 2026 | $11.52 | $11.825 | $11.31 | $11.60 | 733.23K |
| Jul 22, 2026 | $11.16 | $11.79 | $11.12 | $11.70 | 1.42M |
| Jul 21, 2026 | $10.62 | $11.30 | $10.50 | $11.25 | 952.45K |
| Jul 20, 2026 | $10.90 | $11.2242 | $10.59 | $10.65 | 620.36K |
Latest PHAT news
The latest Smart Investors Daily articles mentioning PHAT.
Stock researchCompany · Overview
PHAT research
Overview
Company profile and research snapshot.
Company profile
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.40
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 31, 2026 | Guggenheim | Buy | — |
| Jul 30, 2026 | Needham | Buy | — |
| Jun 17, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 27, 2026 | Barclays | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 31, 2026
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.
Benzinga · Jul 31, 2026
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
SeekingAlpha · Jul 30, 2026
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call July 30, 2026 8:00 AM EDTCompany ParticipantsEric Sciorilli - Director of Business Development...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
